Concord Biotech

BSE: 543960 30 Jul 2025

Healthcare

₹ 1846

Concord Biotech Limited specializes in Pharmaceuticals within the Healthcare sector.

Concord Biotech

BSE: 543960 30 Jul 2025

Healthcare

₹ 1846

Concord Biotech Limited specializes in Pharmaceuticals within the Healthcare sector.

Book Value

173.0

Dividend Yield

0.48%

Debt to Equity

0.0

Stock P/E

51.6

Market Cap

19,180 Cr

Concord Biotech - Share Price & Details

Market Cap

₹19,180

High /Low

2,664 / 1,345

Stock P/E

51.6

Book Value

₹173.0

Dividend Yield

0.48

ROCE

29.5

ROE

₹22.3

Face Value

1.0

PEG Ratio

1.75

EVEBITDA

₹34.9

Debt

2.97

CMP / FCF

139.0

Debt to equity

₹0.0

NP Ann

372

High price all time

2,664

Piotroski score

₹6.0

Graham Number

372.0

No. Eq. Shares

10.5

Net CF

₹-14.2

Net profit

372

Price to book value

10.6

Interest Coverage

₹934.0

Low price all time

900.0

Industry PE

34.0

Reserves

₹1,802

Free Cash Flow

₹134

Price Chart

Volume Chart

Peer Comparison

Stock	Total Income	Net Profit	Net Sales	EPS	Market Cap (in Cr)	P/E
FABINO ENTERPRISES LIMITED	NA	NA	NA	NA	5.46	91.0
Triochem Products Ltd.,	3.25	-4.52	NA	-18.44	0
Concord Biotech Limited	4,392.68	1,419.38	4,298.84	13.57	19,180	51.6
NEULAND LABORATORIES LTD.	3,358.24	277.34	3,283.60	21.62	17794	85.4
NATCO PHARMA LTD.	12,195.00	4,281.00	11,574.00	23.90	17387	9.22

Peer Comparison Chart

About Concord Biotech

Concord Biotech Limited, with Security Code 543960, is a leading player in the Pharmaceuticals industry, categorized under the Healthcare sector, offering Equity instruments.

Latest News

Concord Biotech Limited (543960)’s Trend in 2025 - Explosive portfolio gains

(24 Jul 2025)

Concord Biotech Limited (543960)'s Trend in 2025 ✌️【Trading Ideas】✌️ With a focus on accuracy and timing, we've built a system that helps...

Can Concord Biotech Limited (543960) Maintain Its Valuation - Free Stock Market Real-Time Monitoring

(23 Jul 2025)

Can Concord Biotech Limited (543960) Maintain Its Valuation ✌️【Market Discussions】✌️ Don't miss out on the next 200%+ opportunity...

Where Could Concord Biotech Limited (CONCORDBIO) Be Headed - Game-changing capital returns

(23 Jul 2025)

Where Could Concord Biotech Limited (CONCORDBIO) Be Headed ✌️【Stock Analysis】✌️ With the right insights, 200% returns are not luck — they're...

Can Concord Biotech Limited (543960) Maintain Its Valuation - High-velocity gains

(23 Jul 2025)

Can Concord Biotech Limited (543960) Maintain Its Valuation ✌️【Stock Analysis】✌️ Join our platform for accurate stock predictions and...

Concord Biotech Limited (543960) to Launch New Product Line - Explosive wealth accumulation

(23 Jul 2025)

Concord Biotech Limited (543960) to Launch New Product Line ✌️【Investment News】✌️ Achieve investment success by combining expert insight,...

Concord Biotech Limited (543960) to Launch New Product Line - Robust investment performance

(23 Jul 2025)

Concord Biotech Limited (543960) to Launch New Product Line ✌️【Investor Updates】✌️ Join now to receive real-time alerts on fast-moving...

Quarterly Table

Standalone Consolidated

Metrics	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	194.8	262.3	240.8	319.0	215.8	310.2	244.2	429.9
Expenses	122.7	143.2	134.9	184.7	134.5	173.5	146.3	239.4
Operating Profit	72.2	119.2	105.9	134.3	81.3	136.7	98.0	190.5
OPM %	37.03%	45.43%	43.99%	42.1%	37.66%	44.06%	40.11%	44.31%
Other Income	6.7	8.1	8.2	10.8	10.3	10.0	14.7	9.4
Interest	0.8	0.8	0.5	0.5	0.2	0.1	0.1	0.1
Depreciation	13.0	13.3	13.5	13.7	13.2	13.3	13.3	14.6
Profit before tax	65.0	113.2	100.1	130.9	78.2	133.3	99.3	185.2
Tax %	-25.4%	-25.3%	-25.5%	-25.7%	-25.5%	-26%	-25.4%	-23.3%
Net Profit	48.5	84.5	74.6	97.2	58.2	98.7	74.1	141.9
EPS in Rs	4.63	8.08	7.13	9.29	5.57	9.43	7.08	0

Metrics	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025
Sales	194.8	262.3	240.8	319.0	215.8	310.2	244.2	429.9
Expenses	122.7	146.6	134.9	186.9	134.5	176.5	146.3	240.9
Operating Profit	72.2	115.7	105.9	132.1	81.3	133.7	98.0	188.9
OPM %	37.03%	44.11%	43.99%	41.41%	37.66%	43.11%	40.11%	43.95%
Other Income	6.7	8.1	8.2	10.8	10.3	10.0	14.7	9.4
Interest	0.8	0.8	0.5	0.5	0.2	0.1	0.1	0.1
Depreciation	13.0	13.3	13.5	13.7	13.2	13.3	13.3	14.6
Profit before tax	65.0	109.7	100.1	128.7	78.2	130.3	99.3	183.6
Tax %	-25.4%	-25.3%	-25.5%	-25.7%	25.5%	26%	25.4%	-23.3%
Net Profit	54.5	81.0	77.6	95.0	59.6	95.7	75.9	140.4
EPS in Rs	5.21	7.74	7.41	9.08	5.7	9.15	7.26	0

Shareholding Distribution

Shareholding Pattern

Compounded Data

Consolidated

Standalone

Compounded Sales Growth
10 Years:	0%
5 Years:	18%
3 Years:	18%
TTM:	12%

Compounded Profit Growth
10 Years:	0%
5 Years:	20%
3 Years:	9%
TTM:	9%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	5%

Compounded Sales Growth
10 Years:	0%
5 Years:	0%
3 Years:	18%
TTM:	12%

Compounded Profit Growth
10 Years:	0%
5 Years:	0%
3 Years:	9%
TTM:	7%

Stock Price CAGR
10 Years:	0%
5 Years:	0%
3 Years:	0%
1 Year:	5%

All Deals

Date	Stock	Party	Deal	Acq. Mode	Trans.	Quan.	Price	Value

Concord Biotech

Concord Biotech

Concord Biotech - Share Price & Details

Price Chart

Volume Chart

Peer Comparison

Peer Comparison Chart

About Concord Biotech

Latest News

Concord Biotech Limited (543960)’s Trend in 2025 - Explosive portfolio gains

Can Concord Biotech Limited (543960) Maintain Its Valuation - Free Stock Market Real-Time Monitoring

Where Could Concord Biotech Limited (CONCORDBIO) Be Headed - Game-changing capital returns

Can Concord Biotech Limited (543960) Maintain Its Valuation - High-velocity gains

Concord Biotech Limited (543960) to Launch New Product Line - Explosive wealth accumulation

Concord Biotech Limited (543960) to Launch New Product Line - Robust investment performance

Concord Biotech Limited (CONCORDBIO) Announces Strategic Shift - Dynamic investment growth

Can Concord Biotech Limited (543960) Maintain Its Valuation - Breakthrough capital growth

Concord Biotech Limited (CONCORDBIO) Sees Unusual Trading Volume - Tremendous gains

Concord Biotech Limited (CONCORDBIO) Announces Strategic Shift - High-yield investments

Stock to buy today: Concord Biotech (₹1,797.15)

Briefs: J B Chemicals and Pharmaceuticals, Concord Biotech and Gland Pharma

Concord Biotech Limited receives EIR from USFDA for API facility at Dholka

Concord Biotech Shows Strong Performance Amid Technical Evaluation Adjustments

Concord Biotech edges higher on value buying; trades above 1

Concord Biotech Standalone March 2025 Net Sales at Rs 429.88 crore, up 34.77% Y-o-Y

Market Participants Recognise Concord Biotech Limited's (NSE:CONCORDBIO) Earnings Pushing Shares 30% Higher

Concord Biotech Shows Resilience Amid Mixed Technical Indicators and Market Trends

Concord Biotech Limited (NSE:CONCORDBIO) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?

Concord Biotech share price pops 6% on healthy Q4 nos; profit zooms 48% YoY

Concord Biotech Faces Mildly Bearish Shift Amid Declining Financial Performance

Declining Stock and Solid Fundamentals: Is The Market Wrong About Concord Biotech Limited (NSE:CONCORDBIO)?

V MART RETAIL LTD LEADS LOSERS IN A GROUP

USFDA inspection at Concord Biotech’s API facility at Dholka

Concord Biotech Faces Technical Shift Amid Declining Sales and Profit Metrics

Concord Biotech Shares Surge 5% on Receiving USFDA Final Approval

Concord Biotech Faces Market Sentiment Shift Amid Declining Sales and Profits

Pharma stock jumps 9% receiving board’s approval to invest ₹6.9 Cr in Clean Max

This biotech stock falls over 30% in two days after Q3 earnings, wiping out ₹1,600 crore from Rakesh Jhunjhunwala’s portfolio

Earnings Miss: Here's What Concord Biotech Limited (NSE:CONCORDBIO) Analysts Are Forecasting For Next Year

Concord Biotech shares plunge 16% on reporting Q3 results; PAT down 2% YoY

Concord Biotech shares locked in 20% lower circuit after weak Q3 earnings

Concord Biotech shares tumble 16% after weak Q3 earnings

Concord Biotech Ltd Slips 10.64%

Trade Spotlight: How should you trade Escorts Kubota, NALCO, BSE, Minda Corporation, Concord Biotech,...

Concord Biotech Stock Declines 3.1% on January 15, 2025, Despite Strong Market Position

Concord Biotech Reports 4.25% Gain on January 13, 2025, Outperforming Sector by 4.45%

CONCORD BIOTECH Share Price Today Down 4%

Concord Biotech Share Price Up 8.87% To ₹2,401 – Analysts Eye Future Potential

Concord Biotech Gains 3.21% on December 26, Outperforming Sector by 2.64%

Concord Biotech Posts 4.84% Gain, Ending Four-Day Decline

CONCORD BIOTECH Share Price Today Up 4%

Upcoming IPO: Concord Enviro Systems public offer to open on December 19. Check price band, issue size and more | Stock Market News

Concord Biotech invests $10 lakh in Palvella Therapeutics

Concord Biotech Invests in Palvella Therapeutics for Groundbreaking Skin Drug

Concord Biotech invests USD 10 lakh in Palvella Therapeutics

Concord Biotech's Stock Soars 3.08%, Outperforms Sector and Sensex

Concord Biotech - Bullish Momentum: 10 stocks with White Marubozu Pattern on November 29

Concord Biotech's Stock Soars, Outperforms Sector and Sensex with Impressive Gains

Concord Biotech's Stock Performance Soars, MarketsMOJO Gives 'Buy' Call

Stock Radar: 50% rally in 1 year; wait for confirmation of rounding bottom pattern to go long in Concord Biotech

What should investors do with Concord Biotech?

Stock Radar: 50% rally in 1 year; wait for confirmation of rounding bottom pattern to go long in Concord B

Concord Biotech Consolidated September 2024 Net Sales at Rs 310.18 crore, up 18.23% Y-o-Y

Amber Enterprises India Ltd leads gainers in 'A' group

Jhunjhunwala stock portfolio down 13% amid market correction; top 5 stocks fall up to 24%

Concord Biotech Reports Strong Financial Results, Receives 'Buy' Call from MarketsMOJO

Is this Jhunjhunwala-backed pharma stock still a buy after 30% correction?

Concord Biotech Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Concord Biotech Second Quarter 2025 Earnings: Beats Expectations

Concord Biotech Standalone September 2024 Net Sales at Rs 310.18 crore, up 18.23% Y-o-Y

Is Concord Biotech Limited's (NSE:CONCORDBIO) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Concord Biotech consolidated net profit rises 18.17% in the September 2024 quarter

Concord Biotech's Stock Sees Temporary Dip, But Remains a Strong Player in Pharma Industry

Concord Biotech Receives 'Hold' Rating from MarketsMOJO, Strong Fundamentals and Growth Potential Remain

Concord Biotech - Concurrent Gainers: 12 stocks that gained for 5 days in a row

Concord Biotech's Stock Surges 5.45%, Outperforms Sector and Receives 'Buy' Call from MarketsMOJO

CONCORD BIOTECH Share Price Today Up 7%

Concord Biotech's Stock Soars, Outperforms Sector and Sensex with Consistent Growth

Concord Biotech Receives 'Buy' Rating from MarketsMOJO, Strong Fundamentals and Bullish Trend Drive Upgrade

Concord Biotech's Stock Sees 4.27% Increase, Outperforms Sector and Sensex